 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ALZ002 / AnnJi Pharma, Fortress
Trial completion: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients (clinicaltrials.gov) - Aug 15, 2024
P1/2, N=25, Completed, Sponsor: AnnJi Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed
- | ALZ002 / AnnJi Pharma, Fortress
Enrollment closed: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients (clinicaltrials.gov) - Dec 27, 2023
P1/2, N=24, Active, not recruiting, Sponsor: AnnJi Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ALZ002 / AnnJi Pharma, Fortress
Trial completion date, Trial primary completion date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients (clinicaltrials.gov) - Oct 30, 2023
P1/2, N=24, Recruiting, Sponsor: AnnJi Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- || ALZ002 / AnnJi Pharma, Fortress
Enrollment open, Trial initiation date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients (clinicaltrials.gov) - Feb 9, 2023
P1/2, N=24, Recruiting, Sponsor: AnnJi Pharmaceutical Co., Ltd.
Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Mar 2024 Not yet recruiting --> Recruiting | Initiation date: Nov 2022 --> Feb 2023
- || ALZ002 / AnnJi Pharma, Fortress
New P1/2 trial: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients (clinicaltrials.gov) - Aug 26, 2022
P1/2, N=24, Not yet recruiting, Sponsor: AnnJi Pharmaceutical Co., Ltd.
- | ALZ002 / AnnJi Pharma
Journal: Diketo-Ketoenol Tautomers in Curcuminoids: Synthesis, Separation of Tautomers, and Kinetic and Structural Studies. (Pubmed Central) - Aug 11, 2022
Two different polymorphs of this API have been microscopically identified in the X-ray sample and manually separated, and a solid-state NMR study of the two polymorphs has also been performed. This work reports on the slow kinetics of diketo-ketoenol tautomerization in particular solvents that allow the separation and full characterization of both curcuminoids' tautomers.
- | ALZ002 / AnnJi Pharma, omaveloxolone (RTA 408) / Reata
Preclinical, Journal: In Vitro Efficacy and Molecular Mechanism of Curcumin Analog in Pathological Regulation of Spinocerebellar Ataxia Type 3. (Pubmed Central) - Jul 29, 2022
Unlike other nuclear factor erythroid-2-related factor 2 (Nrf2) activators, the mechanism of action of curcumin analog, ASC-JM17 (JM17), in regulating oxidative homeostasis remains unknown...Presently, we compared actions of JM17 with those of known Nrf2 activators, omaveloxolone (RTA-408) and dimethyl fumarate (DMF), using human neuroblastoma SK-N-SH cells with stable transfection of full-length ataxin-3 protein with 78 CAG repeats (MJD78) to clarify the resulting pathological mechanism by assaying mitochondrial function, mutant ataxin-3 protein toxicity, and oxidative stress...It showed that activation of Nrf2 in response to ROS generated in mitochondria could play an import role in the benefit of JM17. This study presents the diversified regulation of JM17 in a pathological process and helped develop more effective therapeutic strategies for SCA3.
- ||| ALZ002 / AnnJi Pharma, Fortress
Trial completion: A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers (clinicaltrials.gov) - Aug 18, 2021
P1, N=72, Completed, Sponsor: Allianz Pharmascience Limited
This study presents the diversified regulation of JM17 in a pathological process and helped develop more effective therapeutic strategies for SCA3. Recruiting --> Completed
- || atabecestat (JNJ-54861911) / J&J
Clinical, Journal: Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. (Pubmed Central) - Jun 26, 2021
P2, P2a
Recruiting --> Completed Atabecestat was associated with trend toward declines in cognition, and elevation of liver enzymes.
- || ALZ002 / AnnJi Pharma, Fortress
Trial completion date, Trial primary completion date: A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers (clinicaltrials.gov) - Jan 13, 2021
P1, N=72, Recruiting, Sponsor: Allianz Pharmascience Limited
Atabecestat was associated with trend toward declines in cognition, and elevation of liver enzymes. Trial completion date: Jan 2021 --> Aug 2021 | Trial primary completion date: Dec 2020 --> May 2021
- | ALZ002 / AnnJi Pharma, Fortress
New P1 trial: A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers (clinicaltrials.gov) - May 18, 2020
P1, N=72, Recruiting, Sponsor: Allianz Pharmascience Limited